CN113679648A - Wet tissue with sterilization and inflammation diminishing functions and preparation method thereof - Google Patents
Wet tissue with sterilization and inflammation diminishing functions and preparation method thereof Download PDFInfo
- Publication number
- CN113679648A CN113679648A CN202111028394.8A CN202111028394A CN113679648A CN 113679648 A CN113679648 A CN 113679648A CN 202111028394 A CN202111028394 A CN 202111028394A CN 113679648 A CN113679648 A CN 113679648A
- Authority
- CN
- China
- Prior art keywords
- parts
- bisabolol
- sterilization
- wet tissue
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 55
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 48
- 238000004659 sterilization and disinfection Methods 0.000 title claims abstract description 45
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 37
- 230000003467 diminishing effect Effects 0.000 title claims abstract description 28
- 230000006870 function Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 75
- 239000000284 extract Substances 0.000 claims abstract description 61
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 58
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 58
- 239000007788 liquid Substances 0.000 claims abstract description 53
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 48
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229940036350 bisabolol Drugs 0.000 claims abstract description 48
- 239000004094 surface-active agent Substances 0.000 claims abstract description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229920001661 Chitosan Polymers 0.000 claims abstract description 37
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 35
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960003639 laurocapram Drugs 0.000 claims abstract description 32
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 32
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 30
- 229960000367 inositol Drugs 0.000 claims abstract description 30
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000002156 mixing Methods 0.000 claims abstract description 20
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000010438 heat treatment Methods 0.000 claims abstract description 14
- 238000002791 soaking Methods 0.000 claims abstract description 12
- 241001116389 Aloe Species 0.000 claims description 17
- 235000011399 aloe vera Nutrition 0.000 claims description 17
- 235000002020 sage Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 12
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 claims description 10
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 10
- 244000042664 Matricaria chamomilla Species 0.000 claims description 10
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 10
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000005910 alkyl carbonate group Chemical group 0.000 claims description 7
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 7
- 239000004800 polyvinyl chloride Substances 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000012676 herbal extract Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 2
- 244000234609 Portulaca oleracea Species 0.000 claims 2
- 244000178231 Rosmarinus officinalis Species 0.000 claims 2
- 240000001949 Taraxacum officinale Species 0.000 claims 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims 1
- 240000006891 Artemisia vulgaris Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 34
- 201000004624 Dermatitis Diseases 0.000 abstract description 4
- 208000010668 atopic eczema Diseases 0.000 abstract description 3
- 208000014617 hemorrhoid Diseases 0.000 abstract description 3
- 229940045110 chitosan Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 37
- 230000000844 anti-bacterial effect Effects 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 34
- 239000000243 solution Substances 0.000 description 18
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 241000245665 Taraxacum Species 0.000 description 10
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 8
- 241000219304 Portulacaceae Species 0.000 description 8
- 241001529742 Rosmarinus Species 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 239000002344 surface layer Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 240000007164 Salvia officinalis Species 0.000 description 6
- 235000002912 Salvia officinalis Nutrition 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 241000628997 Flos Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000588986 Alcaligenes Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940006091 aloe polysaccharide Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47K—SANITARY EQUIPMENT NOT OTHERWISE PROVIDED FOR; TOILET ACCESSORIES
- A47K10/00—Body-drying implements; Toilet paper; Holders therefor
- A47K10/16—Paper towels; Toilet paper; Holders therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a wet tissue with sterilization and inflammation diminishing functions and a preparation method thereof, and relates to the technical field of sanitary products. The wet tissue comprises non-woven fabrics and liquid medicine, wherein the liquid medicine comprises the following components: traditional Chinese medicine extract, bisabolol, laurocapram, inositol, chitosan quaternary ammonium salt and surfactant. The preparation method comprises mixing bisabolol with ethanol, adding Chinese medicinal extract, heating at 40-60 deg.C for 20-30min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 6-7 to obtain medicinal liquid, and soaking non-woven fabrics in the medicinal liquid for 10-20 min. The wet tissue has good sterilization and inflammation diminishing functions, and can prevent anal eczema and hemorrhoids. The preparation method provided by the invention mutually promotes the effects of the components, so that the wet tissue has better sterilization and anti-inflammation functions.
Description
Technical Field
The invention relates to the technical field of sanitary products, in particular to a wet tissue with sterilization and inflammation diminishing functions and a preparation method thereof.
Background
Paper towels are the most common paper for daily use, are one of essential basic materials for modern human life, and the production capacity and the consumption amount of the paper towels are on the trend of increasing year by year along with the improvement of the living standard of people. At present, although paper of napkin paper and toilet paper which are commonly used by people is soft, and the sanitary index also accords with the sanitary standard, the antibiosis effect is not obvious, especially for people with patients around the anus, the common toilet paper can not thoroughly eliminate bacteria around the anus, and a lot of unnecessary troubles and pains are brought to people.
At present, more than 70 percent of people suffer from hand-foot-and-mouth diseases, hemorrhoids, anal eczema and the like with different degrees, one reason is that food is gradually refined, the daily intake of fiber content is very small, and therefore digestive organs cannot be exercised, so that the intestinal function is weakened, constipation is difficult, and anorectal diseases are caused; the second reason is that no ideal paper towel exists so far, and the common toilet paper has no health care function and has the greatest defect that the common toilet paper cannot be cleaned completely when stains are cleaned, so that the stains can corrode hands, feet, mouths and anus for a long time, and various bacteria grow to cause diseases.
Disclosure of Invention
The invention aims to provide a wet tissue with sterilization and inflammation diminishing functions, which has good sterilization and inflammation diminishing functions and can prevent anal eczema and hemorrhoids.
The invention also aims to provide a preparation method of the wet tissue with the sterilization and inflammation diminishing functions, which mutually promotes the effects of the components and ensures that the wet tissue has better sterilization and inflammation diminishing functions.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides a wet tissue with sterilization and inflammation diminishing functions, which comprises non-woven fabrics and liquid medicine, wherein the liquid medicine comprises the following components in parts by weight: 10-20 parts of traditional Chinese medicine extract, 0.1-2 parts of bisabolol, 1-5 parts of laurocapram, 2-6 parts of inositol, 1-10 parts of chitosan quaternary ammonium salt and 2-8 parts of surfactant.
The invention provides a preparation method of a wet tissue with sterilization and inflammation diminishing functions, which comprises the following steps:
mixing bisabolol with ethanol, adding Chinese medicinal extract, heating at 40-60 deg.C for 20-30min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 6-7 to obtain medicinal liquid, and soaking non-woven fabric in the medicinal liquid for 10-20 min.
The wet tissue with the sterilization and inflammation diminishing functions and the preparation method of the wet tissue with the sterilization and inflammation diminishing functions provided by the embodiment of the invention have at least the following beneficial effects: the bisabolol has antibacterial and anti-inflammatory effects, the traditional Chinese medicine extract has antibacterial and anti-inflammatory effects, the bisabolol and the traditional Chinese medicine extract are used in a matching way, the antibacterial and antibacterial effects of the bisabolol and the traditional Chinese medicine extract are mutually promoted, and the anti-inflammatory effect is mutually synergistic, so that the antibacterial, antibacterial and anti-inflammatory effects of the liquid medicine are better. Secondly, laurocapram and inositol have good osmosis and biocompatibility, and the biocompatibility of the laurocapram and the inositol can ensure that the mixing and dissolving effect of bisabolol and the traditional Chinese medicine extract is better; the skin surface layer can be better permeated by the bisabolol by utilizing the osmosis, and the effective components of the traditional Chinese medicine extract can be better permeated into the skin surface layer, so that the skin can be deeply cleaned, and the skin can be better sterilized and disinfected. The chitosan quaternary ammonium salt has good antibacterial property, and the chitosan quaternary ammonium salt is matched with the bisabolol and the traditional Chinese medicine extract for use, so that the antibacterial property, the sterilization property and the bacteriostatic property are combined with each other, and the sterilization effect of the liquid medicine can be further enhanced. The chitosan quaternary ammonium salt also has good moisture absorption and moisture retention effects, and can be used in combination with a surfactant to enhance the wettability of the liquid medicine, so that the dry and water-deficient skin surface after the wet tissue is used can be avoided, and the comfort level of a user is improved.
In the invention, because the bisabolol is difficult to dissolve in water, the bisabolol is required to be firstly mixed with ethanol to be dissolved, and then is mixed with the traditional Chinese medicine extract to be heated for 20-30min at 40-60 ℃. At the temperature, the dissolution speed of the bisabolol and the traditional Chinese medicine extract can be accelerated, specifically, the molecular activities in the solution are enhanced, and the molecules collide with each other, so that the mixing effect of the bisabolol and the traditional Chinese medicine extract is better. Then sequentially adding the chitosan quaternary ammonium salt, the laurocapram, the cyclohexanehexol and the surfactant, and sequentially adding the components, so that the synergistic promotion effect among the components is better, and further the sterilization and inflammation diminishing effects of the liquid medicine are enhanced. The pH value of the liquid medicine is adjusted to be 6-7, because under the weak acid condition, the penetration promoting effect of laurocapram and inositol is better, and then the sterilization and inflammation diminishing components in the liquid medicine are better penetrated into the surface layer of the skin, so that the sterilization and inflammation diminishing effects on the skin are better, the skin cleaning degree is obviously improved, and the bacterial growth is effectively prevented.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
The wet tissue with the sterilization and inflammation diminishing functions comprises non-woven fabrics and liquid medicine, wherein the liquid medicine comprises the following components in parts by weight: 10-20 parts of traditional Chinese medicine extract, 0.1-2 parts of bisabolol, 1-5 parts of laurocapram, 2-6 parts of inositol, 1-10 parts of chitosan quaternary ammonium salt and 2-8 parts of surfactant.
Bisabolol is an organic compound with molecular formula C15H26OIs a non-toxic sesquiterpene alcohol existing in natural essential oil. In detail, the bisabolol is alpha-bisabolol, the alpha-bisabolol has good stability and skin compatibility, and the alpha-bisabolol also has anti-inflammatory property and bacteriostatic activity. The alpha-bisabolol and the traditional Chinese medicine extract are matched for use, the antibacterial and bactericidal effects of the alpha-bisabolol and the traditional Chinese medicine extract are mutually promoted, and the anti-inflammatory effect is mutually synergistic, so that the antibacterial, antibacterial and anti-inflammatory effects of the liquid medicine are better.
Laurocapram, which can safely promote the penetration and absorption of active ingredients on skin, is a novel efficient transdermal penetration enhancer and has good promoting effect on a plurality of hydrophilic and lipophilic synthetic drugs and natural drugs. The obvious osmosis effect of the inositol can improve the metabolism of skin layer fiber cells, protect the keratinocyte from water loss caused by hypertonic pressure, and maintain the cell size/volume and water balance of the keratinocyte under the hypertonic condition. In detail, laurocapram and inositol have good osmosis and biocompatibility, and the biocompatibility of the laurocapram and the inositol can ensure that the alpha-bisabolol and the traditional Chinese medicine extract have better mixing and dissolving effects; the alpha-bisabolol can better permeate into the surface layer of the skin by utilizing the osmosis, and the effective components of the traditional Chinese medicine extract can better permeate into the surface layer of the skin, so that the skin can be deeply cleaned, and the skin can be better sterilized and disinfected.
The chitosan quaternary ammonium salt is a chitosan advanced derivative prepared by chemically modifying marine organism chitosan, has good water solubility, strong hygroscopicity, good compatibility and biodegradability, and also has good antibacterial property, film forming property, cation adsorbability, moisture absorption and retention property, flocculation property, antistatic property and the like. Surfactants (surfactants), which are substances that can significantly reduce the surface tension of a target solution, generally have fixed hydrophilic and lipophilic groups that can be oriented on the surface of the solution. The molecular structure of the surfactant has an amphoteric nature: one end is a hydrophilic group, and the other end is a hydrophobic group; the hydrophilic group is often a polar group, such as carboxylic acid, sulfonic acid, sulfuric acid, amino or amino groups and salts thereof, hydroxyl, amide, ether linkages, and the like may also be used as the polar hydrophilic group; and the hydrophobic group is often a non-polar hydrocarbon chain, such as a hydrocarbon chain of 8 or more carbon atoms. The surfactant reduces the surface tension of water by adsorbing at the gas-liquid two-phase interface, and also reduces the oil-water interfacial tension by adsorbing between the liquid interfaces. Surfactants can enhance the wetting, emulsifying, and foaming properties of the solution.
The chitosan quaternary ammonium salt has good antibacterial property, and the chitosan quaternary ammonium salt is matched with the bisabolol and the traditional Chinese medicine extract for use, so that the antibacterial property, the sterilization property and the bacteriostatic property are combined with each other, and the sterilization effect of the liquid medicine can be further enhanced. The chitosan quaternary ammonium salt also has good moisture absorption and moisture retention effects, and can be used in combination with a surfactant to enhance the wettability of the liquid medicine, so that the dry and water-deficient skin surface after the wet tissue is used can be avoided, and the comfort level of a user is improved.
In the embodiment, the traditional Chinese medicine extract comprises, by weight, 2-10 parts of aloe, 1-5 parts of folium artemisiae argyi, 3-6 parts of chamomile, 2-6 parts of rosemary, 3-7 parts of sage, 4-10 parts of dandelion and 5-10 parts of purslane.
Aloe has antibacterial effect, and Aloe tincture (Aloetin) in Aloe is a substance with strong antibacterial effect, and can kill fungi, mold, bacteria, virus, etc., and inhibit and eliminate development and reproduction of pathogen. Aloe also has antiinflammatory effect, and its bradykinin peptidase and angiotonia are combined to resist inflammation, especially Aloe polysaccharide can enhance human body resistance to diseases, and cure chronic diseases such as dermatitis, chronic nephritis, cystitis, bronchitis, etc.
The folium artemisiae argyi extract has weak bacteriostatic action on pathogenic dermatophytes, the folium artemisiae argyi volatile oil has inhibitory action on cocci and most gram-negative bacilli, the smoked folium artemisiae argyi is used as an air disinfectant, has killing or inhibitory action on staphylococcus aureus, beta hemolytic streptococcus, escherichia coli, proteus, diphtheria bacillus, typhoid fever bacillus, paratyphoid bacillus, pseudomonas aeruginosa, bacillus subtilis, alcaligenes, human mycobacterium tuberculosis and the like, and also has bacteriostatic action on various pathogenic fungi.
The chamomile oil has the effects of clearing heat and expelling damp, also has the effect of resisting pathogenic microorganisms, and also has the effects of relieving and diminishing inflammation. Rosemary has effects of tranquilizing mind and relieving pain, and the volatile oil has antibacterial, antiinflammatory and antioxidant effects. The volatile oil of herba Salvia officinalis and herba Salvia officinalis has antibacterial, antitoxic and antidotal effects. The dandelion contains dandelion alcohol, taraxacin, choline, organic acid, inulin and the like, has good effects of clearing heat, detoxifying and diminishing inflammation, and mainly has strong bactericidal effect on staphylococcus aureus drug-resistant strains and hemolytic streptococcus. Purslane has the functions of clearing heat, promoting diuresis, detoxifying, reducing swelling and diminishing inflammation.
The folium artemisiae argyi, the aloe and the dandelion in the traditional Chinese medicine extract have good antibacterial and bactericidal effects, and the antibacterial and bactericidal effects can be enhanced when the extracts are used in combination. In addition, aloe, chamomile, rosemary, dandelion and purslane all have good anti-inflammatory effects, and the anti-inflammatory effect and the antibacterial and bactericidal effect are combined, so that the skin cleaning degree of the extract can be obviously improved. The chamomile, the dandelion and the purslane also have the heat-clearing effect, and the heat-clearing effect is combined with the anti-inflammation effect, so that the skin cleaning effect can be further enhanced. The skin care lotion, the surfactant and the chitosan quaternary ammonium salt can clean the skin, and can also moisturize the skin, so that the skin is prevented from being dried due to water shortage caused by over-cleaning.
The surfactant in this embodiment may be one or more of sodium polyvinyl chloride alkyl carbonate, sodium acyl sulfonate, alkyl polyglucoside, and alkyl alcohol monoethanolamide.
The sodium polyvinyl chloride alkyl carbonate and the sodium acyl sulfonate are both anionic surfactants, and the sodium polyvinyl chloride alkyl carbonate belongs to a surfactant with good degreasing capability and has small irritation to skin and mucous membranes (such as eyelids). The sodium acylsulfonate has excellent detergency, low skin irritation, excellent skin affinity, good skin feeling during washing or after washing, no excessive dryness of the skin, and remarkable tenderness. The alkyl alcohol monoethanolamide and the alkyl polyglucoside are both nonionic surfactants, are prepared from natural plants as raw materials, have no any irritation and toxicity to skin and environment, have moderate cleaning power, and are new popular low-sensitivity active agents. The surfactant and the chitosan quaternary ammonium salt are combined for use, and the wettability of the liquid medicine is further enhanced through the permeation promoting effect of the surfactant, so that the dry and water-deficient skin surface after the wet tissue is used can be avoided, and the comfort level of a user is improved.
A preparation method of a wet tissue with sterilization and anti-inflammation functions comprises the following steps:
mixing bisabolol and ethanol, adding Chinese medicinal extract, heating at 40-60 deg.C for 20-30min, stirring once every 8-12min for 3-5min during heating, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexadenol and surfactant, adjusting pH to 6-7 to obtain medicinal liquid, sterilizing non-woven fabric for 10-20min, and soaking the non-woven fabric in the medicinal liquid for 10-20 min.
In this embodiment, since bisabolol is insoluble in water, it is necessary to first mix it with ethanol to dissolve it, and then mix it with the herbal extract and heat it at 40-60 deg.C for 20-30 min. At the temperature, the dissolution speed of the bisabolol and the traditional Chinese medicine extract can be accelerated, specifically, the molecular activities in the solution are enhanced, and the molecules collide with each other, so that the mixing effect of the bisabolol and the traditional Chinese medicine extract is better. Stirring is needed in the heating process, stirring operation is increased, the molecular movement speed in the solution can be further increased, the dissolution speed of the bisabolol and the traditional Chinese medicine extract is further increased, the solution is stirred once every 8-12min, the solution static condition can be continuously broken through multiple times of stirring, the intermolecular movement condition is continuously inhibited, and the bisabolol and the traditional Chinese medicine extract are mixed more thoroughly; stirring for 3-5min each time to ensure that bisabolol and Chinese medicinal extract are uniformly mixed and avoid the situation that the two are not completely and uniformly mixed.
And then sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and a surfactant into the mixed solution of the bisabolol and the traditional Chinese medicine extract, and sequentially adding the components to ensure that the synergistic promotion effect among the components is better, specifically, the chitosan quaternary ammonium salt can enhance the antibacterial property and the moisturizing property, the laurocapram and the cyclohexanehexol enhance the penetration effect, and the surfactant can further enhance the penetration and the moisturizing effect, so that the sterilization and anti-inflammation effects of the liquid medicine are enhanced. The pH value of the liquid medicine is adjusted to be 6-7, because under the weak acid condition, the penetration promoting effect of laurocapram and inositol is better, and then the sterilization and inflammation diminishing components in the liquid medicine are better penetrated into the surface layer of the skin, so that the sterilization and inflammation diminishing effects on the skin are better, the skin cleaning degree is obviously improved, and the bacterial growth is effectively prevented.
The embodiment also comprises sterilizing the non-woven fabrics for 10-20min, and soaking the non-woven fabrics in the liquid medicine for 10-20 min. The non-woven fabrics are sterilized firstly, so that bacteria on the non-woven fabrics can be killed, the cleanliness of the non-woven fabrics is increased, and the safety of the wet tissue in use is improved. Alternatively, the sterilization may be microwave sterilization, ultraviolet sterilization, or ozone sterilization, and the specific manner is not limited. Sterilizing for 10-20min to ensure complete sterilization of the non-woven fabric. The non-woven fabric is directly soaked in the liquid medicine, so that the non-woven fabric can absorb the liquid medicine, the non-woven fabric is soaked for 10-20min, the liquid medicine can completely soak the non-woven fabric, and the liquid medicine content of the wet tissue can relatively thoroughly clean the skin when the wet tissue is used. Optionally, the mass concentration of ethanol is 70% to 75%, and the mass ratio of ethanol to bisabolol is 1: 3. the ethanol with the mass concentration can accelerate the dissolution speed of the bisabolol in the ethanol, and meanwhile, the ethanol has the sterilization and disinfection effects, so that the sterilization effect of the liquid medicine can be further enhanced. In addition, the ethanol can also accelerate the mixing degree of the traditional Chinese medicine extract and the bisabolol, so that the solution has better uniformity.
The preparation method of the traditional Chinese medicine extract comprises the following steps: adding purified water into aloe, folium artemisiae argyi, dandelion and purslane, decocting for 1-2h at 60-70 ℃ to obtain a first solution, extracting chamomile, sage and rosemary for 1-2h at 100-120 ℃ by steam to obtain a second solution, mixing the first solution and the second solution, and concentrating for 30-40min at-5-10 ℃ to obtain the traditional Chinese medicine extract. In the embodiment, aloe, folium artemisiae argyi, dandelion and purslane are decocted for 1-2 hours at 60-70 ℃, the mixed decoction of the traditional Chinese medicines can have good sterilizing and inflammation diminishing effects, and the decoction and extraction at the temperature can avoid the damage of high temperature to the effective components of the medicines, so that the drug effect is weakened; the chamomile, the sage and the rosemary are subjected to steam extraction at the temperature of 100-120 ℃ for 1-2h, because the volatile oil extracts of the chamomile, the sage and the rosemary have good bactericidal effect, relatively pure volatile oil can be obtained through steam extraction, and meanwhile, the steam extraction speed is higher, and the process time can be shortened. Then the mixed solution after being respectively treated is frozen and concentrated, so that the mass density of the effective components in the solution can be improved, and the drug effect of the liquid medicine is better. Optionally, before the concentration, the method further comprises the step of mixing the first solution and the second solution and then centrifuging for 3-10min at the speed of 800-.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
A preparation method of a wet tissue with sterilization and anti-inflammation functions comprises the following steps:
taking 10g of traditional Chinese medicine extract, 0.1g of bisabolol, 1g of laurocapram, 2g of inositol, 1g of chitosan quaternary ammonium salt and 2g of surfactant.
The Chinese medicinal extract comprises 2g of aloe, 1g of folium artemisiae argyi, 3g of chamomile, 2g of rosemary, 3g of sage, 4g of dandelion and 5g of purslane.
Mixing bisabolol with 70% ethanol, adding Chinese medicinal extract, heating at 40 deg.C for 20min, stirring once every 8min for 3min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 6 to obtain medicinal liquid, sterilizing the non-woven fabric for 10min, and soaking the non-woven fabric in the medicinal liquid for 10 min.
In this example, the surfactant is sodium polyvinyl chloride alkyl carbonate.
Example 2
A preparation method of a wet tissue with sterilization and anti-inflammation functions comprises the following steps:
20g of traditional Chinese medicine extract, 2g of bisabolol, 5g of laurocapram, 6g of inositol, 10g of chitosan quaternary ammonium salt and 8g of surfactant are taken.
The Chinese medicinal extract comprises aloe 10g, folium Artemisiae Argyi 5g, flos Chrysanthemi 6g, herba Rosmarini officinalis 6g, herba Salvia officinalis 7g, herba Taraxaci 10g and herba Portulacae 10 g.
Mixing bisabolol with 75% ethanol, adding Chinese medicinal extract, heating at 60 deg.C for 30min, stirring once every 12min for 5min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 7 to obtain medicinal liquid, sterilizing the non-woven fabric for 20min, and soaking the non-woven fabric in the medicinal liquid for 20 min.
In this example, the surfactant is sodium acyl sulfonate.
Example 3
A preparation method of a wet tissue with sterilization and anti-inflammation functions comprises the following steps:
taking 15g of traditional Chinese medicine extract, 1g of bisabolol, 2g of laurocapram, 4g of inositol, 5g of chitosan quaternary ammonium salt and 5g of surfactant.
The Chinese medicinal extract comprises aloe 5g, folium Artemisiae Argyi 3g, flos Chrysanthemi 4g, herba Rosmarini officinalis 5g, herba Salvia officinalis 4g, herba Taraxaci 6g and herba Portulacae 7 g.
Mixing bisabolol with 72% ethanol, adding Chinese medicinal extract, heating at 50 deg.C for 25min, stirring once every 8min for 4min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 6.5 to obtain medicinal liquid, sterilizing the non-woven fabric for 15min, and soaking the non-woven fabric in the medicinal liquid for 15 min.
In this example, the surfactant is an alkyl polyglucoside.
Example 4
A preparation method of a wet tissue with sterilization and anti-inflammation functions comprises the following steps:
taking 12g of traditional Chinese medicine extract, 1.5g of bisabolol, 3g of laurocapram, 3g of inositol, 3g of chitosan quaternary ammonium salt and 3g of surfactant.
The Chinese medicinal extract comprises aloe 6g, folium Artemisiae Argyi 4g, flos Chrysanthemi 5g, herba Rosmarini officinalis 3g, herba Salvia officinalis 5g, herba Taraxaci 5g and herba Portulacae 6 g.
Mixing bisabolol with 74% ethanol, adding the Chinese medicinal extract, heating at 45 deg.C for 22min, stirring every 10min for 3.5min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 6.7 to obtain medicinal liquid, sterilizing the non-woven fabric for 12min, and soaking the non-woven fabric in the medicinal liquid for 12 min.
In this example, the surfactant is an alkylol monoethanolamide.
Example 5
A preparation method of a wet tissue with sterilization and anti-inflammation functions comprises the following steps:
taking 16g of traditional Chinese medicine extract, 0.5g of bisabolol, 2.5g of laurocapram, 3.5g of inositol, 7g of chitosan quaternary ammonium salt and 5.5g of surfactant.
The Chinese medicinal extract comprises aloe 5.5g, folium Artemisiae Argyi 3.5g, flos Chrysanthemi 4.5g, herba Rosmarini officinalis 5.5g, herba Salvia officinalis 6g, herba Taraxaci 8g and herba Portulacae 9 g.
Mixing bisabolol with 71% ethanol, adding Chinese medicinal extract, heating at 55 deg.C for 28min, stirring every 11min for 4.5min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 6.2 to obtain medicinal liquid, sterilizing the non-woven fabric for 17min, and soaking the non-woven fabric in the medicinal liquid for 17 min.
In this example, the surfactants are sodium polyvinyl chloride alkyl carbonate and alkyl alcohol monoethanolamide.
Example 6
A preparation method of a wet tissue with sterilization and anti-inflammation functions comprises the following steps:
taking 14g of traditional Chinese medicine extract, 1.8g of alpha-bisabolol, 3.8g of laurocapram, 4.7g of inositol, 6.5g of chitosan quaternary ammonium salt and 7.5g of surfactant.
The Chinese medicinal extract comprises 4g of aloe, 4g of folium artemisiae argyi, 5g of chamomile, 4g of rosemary, 6g of sage, 9g of dandelion and 8g of purslane.
Mixing alpha-bisabolol with 73% ethanol, adding the Chinese medicinal extract, heating at 42 deg.C for 21min, stirring once every 9.5min during heating, stirring for 3.8min each time, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexadenol and surfactant, adjusting pH to 6.8 to obtain medicinal liquid, sterilizing the non-woven fabric for 13min, and soaking the non-woven fabric in the medicinal liquid for 14 min.
In this example, the surfactant is sodium polyvinyl chloride alkyl carbonate, alkyl alcohol monoethanolamide, and sodium acyl sulfonate.
1. Irritation test
The wet tissues of examples 1-6 were tested for skin irritation, and the procedure included: taking 12 healthy female rabbits, dividing the rabbits into 2 groups, correspondingly using the wet tissues in the examples 1-6 in each group, specifically, attaching the wet tissues to the vaginal part of the healthy female rabbits, observing the conditions of the vaginal part or the periphery of the vagina of the rabbits after 3 days, wherein the erythema and inflammation conditions are expressed by percentage, 100% represents that the erythema or inflammation conditions are very serious, 0 represents that no erythema or inflammation exists, and the like, and the concrete results are as follows:
TABLE 1 statistics of irritation results
| Examples | 1 | 2 | 3 | 4 | 5 | 6 |
| Erythema | 0 | 3％ | 2％ | 0 | 2％ | 0 |
| Inflammation(s) | 2％ | 1％ | 2％ | 3％ | 0 | 0 |
No irritation: no erythema and inflammation; has irritation: local erythema or inflammation; strong irritation: erythema and inflammation were significant.
As is apparent from Table 1, the wet tissues obtained in examples 1 to 6 were applied to the vaginal part of a healthy female rabbit for 3 days, and then, almost no erythema or inflammation was observed in the vaginal part of the female rabbit. Therefore, the wet tissue prepared by the invention has little irritation, and can be used at different positions.
2. Test of bacteriostatic Effect
The wet tissues obtained in examples 1 to 6 are tested, the test data includes the bacteriostatic effect, and according to the bacteriostatic requirement in the national standard GB15979-2002, the killing rate of escherichia coli and staphylococcus aureus is equal to or greater than 90%, the killing rate of candida albicans is equal to or greater than 90%, and the test results are as follows:
TABLE 2 statistics of bacteriostatic results
| Examples | 1 | 2 | 3 | 4 | 5 | 6 |
| Killing rate of colibacillus | 90％ | 88％ | 90％ | 92％ | 90％ | 93％ |
| Kill rate of staphylococcus aureus | 90％ | 90％ | 87％ | 91％ | 93％ | 92％ |
| Killing rate of Candida albicans | 85％ | 90％ | 90％ | 91％ | 90％ | 91％ |
As can be seen from table 2, the wet tissue prepared by the present invention has a relatively good effect of killing bacteria.
In summary, according to the wet tissue with the sterilization and inflammation diminishing functions and the preparation method of the wet tissue with the sterilization and inflammation diminishing functions provided by the embodiments of the present invention, the bisabolol has the antibacterial and inflammation diminishing effects, the traditional Chinese medicine extract has the antibacterial and inflammation diminishing effects, and the bisabolol and the traditional Chinese medicine extract are used in combination, so that the antibacterial and antibacterial effects of the two are mutually promoted, and the anti-inflammatory effect is mutually synergistic, so that the antibacterial, antibacterial and anti-inflammatory effects of the liquid medicine are better. Secondly, laurocapram and inositol have good osmosis and biocompatibility, and the biocompatibility of the laurocapram and the inositol can ensure that the mixing and dissolving effect of bisabolol and the traditional Chinese medicine extract is better; the skin surface layer can be better permeated by the bisabolol by utilizing the osmosis, and the effective components of the traditional Chinese medicine extract can be better permeated into the skin surface layer, so that the skin can be deeply cleaned, and the skin can be better sterilized and disinfected. The chitosan quaternary ammonium salt has good antibacterial property, and the chitosan quaternary ammonium salt is matched with the bisabolol and the traditional Chinese medicine extract for use, so that the antibacterial property, the sterilization property and the bacteriostatic property are combined with each other, and the sterilization effect of the liquid medicine can be further enhanced. The chitosan quaternary ammonium salt also has good moisture absorption and moisture retention effects, and can be used in combination with a surfactant to enhance the wettability of the liquid medicine, so that the dry and water-deficient skin surface after the wet tissue is used can be avoided, and the comfort level of a user is improved. The preparation method of the invention can mutually promote the effects of the components, thereby ensuring that the wet tissue has better sterilization and anti-inflammation functions.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The wet tissue with the sterilization and inflammation diminishing functions is characterized by comprising non-woven fabrics and liquid medicine, wherein the liquid medicine comprises the following components in parts by weight: 10-20 parts of traditional Chinese medicine extract, 0.1-2 parts of bisabolol, 1-5 parts of laurocapram, 2-6 parts of inositol, 1-10 parts of chitosan quaternary ammonium salt and 2-8 parts of surfactant.
2. The wet tissue as claimed in claim 1, wherein the herbal extract comprises 2-10 parts by weight of aloe, 1-5 parts by weight of mugwort, 3-6 parts by weight of chamomile, 2-6 parts by weight of rosemary, 3-7 parts by weight of sage, 4-10 parts by weight of dandelion and 5-10 parts by weight of purslane.
3. The wet wipe of claim 1, wherein the surfactant is one or more of sodium polyvinyl chloride alkyl carbonate, sodium acyl sulfonate, alkyl polyglucoside, and alkyl alcohol monoethanolamide.
4. The wet wipe of claim 1, wherein the bisabolol is alpha-bisabolol.
5. A method for preparing the wet wipe according to any one of claims 1 to 4, comprising the steps of: mixing bisabolol with ethanol, adding Chinese medicinal extract, heating at 40-60 deg.C for 20-30min, sequentially adding chitosan quaternary ammonium salt, laurocapram, cyclohexanehexol and surfactant, adjusting pH to 6-7 to obtain medicinal liquid, and soaking non-woven fabric in the medicinal liquid for 10-20 min.
6. The preparation method according to claim 5, wherein the mass concentration of the ethanol is 70% to 75%, and the mass ratio of the ethanol to the bisabolol is 1: 3.
7. the method according to claim 5, wherein the stirring is performed every 8 to 12min for 3 to 5min during the heating.
8. The method of claim 5, wherein the method of preparing the herbal extract comprises: adding purified water into aloe, folium artemisiae argyi, dandelion and purslane, decocting for 1-2h at 60-70 ℃ to obtain a first solution, extracting chamomile, sage and rosemary for 1-2h at 100-120 ℃ by steam to obtain a second solution, mixing the first solution and the second solution, and concentrating for 30-40min at-5-10 ℃ to obtain the traditional Chinese medicine extract.
9. The method as claimed in claim 8, further comprising mixing the first solution and the second solution, centrifuging at 1000r/min for 3-10min at 800-.
10. The method of claim 5, further comprising sterilizing the nonwoven fabric for 10-20min before soaking.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111028394.8A CN113679648A (en) | 2021-09-02 | 2021-09-02 | Wet tissue with sterilization and inflammation diminishing functions and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111028394.8A CN113679648A (en) | 2021-09-02 | 2021-09-02 | Wet tissue with sterilization and inflammation diminishing functions and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113679648A true CN113679648A (en) | 2021-11-23 |
Family
ID=78585082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111028394.8A Pending CN113679648A (en) | 2021-09-02 | 2021-09-02 | Wet tissue with sterilization and inflammation diminishing functions and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113679648A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344210A (en) * | 2021-12-25 | 2022-04-15 | 江苏辰安泰生物医药研究院有限公司 | Biomass disinfection wet tissue containing traditional Chinese medicine components and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108606945A (en) * | 2018-05-30 | 2018-10-02 | 高尚朴 | A kind of disinfection wet tissue and preparation method thereof |
| US20200046661A1 (en) * | 2013-07-02 | 2020-02-13 | Ecoplanet Environmental Llc | Volatile Organic Compound Formulations Having Antimicrobial Activity |
| CN113116772A (en) * | 2021-03-07 | 2021-07-16 | 张殿荣 | Traditional Chinese medicine wet tissue with sterilizing and inflammation diminishing functions and preparation method thereof |
-
2021
- 2021-09-02 CN CN202111028394.8A patent/CN113679648A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200046661A1 (en) * | 2013-07-02 | 2020-02-13 | Ecoplanet Environmental Llc | Volatile Organic Compound Formulations Having Antimicrobial Activity |
| CN108606945A (en) * | 2018-05-30 | 2018-10-02 | 高尚朴 | A kind of disinfection wet tissue and preparation method thereof |
| CN113116772A (en) * | 2021-03-07 | 2021-07-16 | 张殿荣 | Traditional Chinese medicine wet tissue with sterilizing and inflammation diminishing functions and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344210A (en) * | 2021-12-25 | 2022-04-15 | 江苏辰安泰生物医药研究院有限公司 | Biomass disinfection wet tissue containing traditional Chinese medicine components and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4788060A (en) | Multiple electrolyte douche and wipe composition | |
| CN103356738B (en) | Skin disinfection gel and its application | |
| HU229230B1 (en) | Medical composition for the treatment of herpes simplex virus and other infectious diseases | |
| CN106176430A (en) | A kind of disposable foam type women bactericidal liquid and preparation method thereof | |
| KR20150102578A (en) | Antibiotic wet tissue, and manufacturing method thereof | |
| CN112048402B (en) | Antibacterial, stain-removing and peculiar smell-removing underwear soap and preparation method thereof | |
| CN108158995A (en) | A kind of gynaecology's anti-bacteria foaming agent containing chitosan and preparation method thereof | |
| CN114146030B (en) | Itching-relieving and relaxing bath lotion and preparation method thereof | |
| CN112957263A (en) | Essence, face washing towel impregnated with essence and preparation process of face washing towel | |
| CN111150778A (en) | A sterilizing disinfectant with high safety and high efficiency for oral mucosa, skin and general articles, and its preparation method | |
| CN106491462A (en) | A kind of cleaning bacteria inhibiting composition and preparation method thereof, the antibacterial wet tissue of Anal cleaning | |
| CN113679648A (en) | Wet tissue with sterilization and inflammation diminishing functions and preparation method thereof | |
| CN111184675A (en) | No-clean disinfection composition, preparation method thereof and no-clean disinfection gel | |
| CN104490679B (en) | A kind of composite bactericidal hand cleanser and preparation method thereof | |
| CN110946818A (en) | Natural herbal skin mucosa disinfectant special for private parts of men | |
| CN106728630A (en) | A kind of anti-inflammation composition and privates care product | |
| RU2638799C2 (en) | Zinc coceth sulphate application in capacity of antibacterial agent for propionibacterium acnes | |
| CN106074783A (en) | A kind of silver ion bacteriostatic gel and preparation method thereof | |
| KR102373422B1 (en) | Composition for vaginal cleaning including functional peptides | |
| CN105193686A (en) | Female care solution and preparation method thereof | |
| CN111481567B (en) | Compound ozone oil and preparation method and application thereof | |
| KR102481754B1 (en) | Antibacterial and deodorant composition including galla rhois | |
| CN113876680A (en) | Plant wet tissue and preparation process thereof | |
| CN113101263A (en) | Skin disinfection microemulsion gel and preparation method thereof | |
| CN108403520A (en) | A kind of chitosan Mrs Chinese herbal medicine conditioning liquid and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211123 |